Literature DB >> 12692415

Hemorrhagic cystitis following allogeneic hematopoietic cell transplantation.

Gyeong-Won Lee1, Je-Hwan Lee, Seong-Jun Choi, Shin Kim, Miee Seol, Woo-Kun Kim, Jung-Shin Lee, Kyoo-Hyung Lee.   

Abstract

We conducted a retrospective study to investigate the incidence, risk factors, and clinical features of hemorrhagic cystitis (HC) following allogeneic hematopoietic cell transplantation (allo-HCT). Adult patients who developed HC after allo-HCT were identified from the HCT database of the Asan Medical Center and their medical records were reviewed. From December 1993 to August 2001, a total of 210 adult patients underwent allo-HCT. Fifty-one patients developed HC with a cumulative incidence of 25.7%. The median onset of HC was post-transplant day 24 (range, -2 to 474), and the median duration was 31 days (range, 8 to 369). Significant risk factors for HC by univariate analysis included diagnosis of chronic myelogenous leukemia (p=0.028), unrelated HCT (p=0.029), grade III-IV acute graft-versus-host disease (GVHD) (p<0.001), extensive chronic GVHD (p=0.001), and positive cytomegalovirus antigenemia between post transplant days 31 and 60 (p=0.031). Multivariate analysis showed that grade III-IV acute GVHD was the most important risk factor for the occurrence of HC after allo-HCT (odds ratio, 3.38; 95% CI, 1.36-8.39). Late-onset HC, which occurred beyond 3 weeks after allo-HCT, was more frequently associated with GVHD than early-onset HC (p=0.007). Our data suggest that a portion of late-onset HC might be a manifestation of GVHD.

Entities:  

Mesh:

Year:  2003        PMID: 12692415      PMCID: PMC3055015          DOI: 10.3346/jkms.2003.18.2.191

Source DB:  PubMed          Journal:  J Korean Med Sci        ISSN: 1011-8934            Impact factor:   2.153


  8 in total

1.  Predictors of the development of surgical complications among hematopoietic stem cell transplantation recipients.

Authors:  Iyad Anabtawi; Fawzi Abdelrahman; Ahamd Alomari; Murad Ba'ba'; Mahmoud Al Masri
Journal:  World J Surg       Date:  2012-05       Impact factor: 3.352

2.  Hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: risk factors, graft source and survival.

Authors:  L E Lunde; S Dasaraju; Q Cao; C S Cohn; M Reding; N Bejanyan; B Trottier; J Rogosheske; C Brunstein; E Warlick; J A H Young; D J Weisdorf; C Ustun
Journal:  Bone Marrow Transplant       Date:  2015-07-13       Impact factor: 5.483

Review 3.  BK virus-associated hemorrhagic cystitis after pediatric stem cell transplantation.

Authors:  Seung Beom Han; Bin Cho; Jin Han Kang
Journal:  Korean J Pediatr       Date:  2014-12-31

4.  Effect of late-onset hemorrhagic cystitis on PFS after haplo-PBSCT.

Authors:  Hailong Yuan; Gang Chen; Jianhua Qu; Ruixue Yang; Maria Muhashi; Gulibadanmu Aizezi; Ming Jiang
Journal:  Open Med (Wars)       Date:  2021-10-05

5.  Incidence of late-onset hemorrhagic cystitis and its effect on PFS in acute leukemia patients after haplo-PBSCT: The 5-year single-center data.

Authors:  Hailong Yuan; Gang Chen; Jianli Xu; Ruixue Yang; Maria Muhashi; Gulibadanmu Aizezi; Ming Jiang
Journal:  Front Oncol       Date:  2022-07-15       Impact factor: 5.738

6.  Ultrasonography in the diagnosis of hemorrhagic cystitis - a complication of bone marrow transplantation in pediatric oncology patients.

Authors:  Urszula Zaleska-Dorobisz; Anna Biel; Dąbrówka Sokołowska-Dąbek; Cyprian Olchowy; Mateusz Łasecki
Journal:  J Ultrason       Date:  2014-09-30

7.  Nursing Management of Haemorrhagic Cystitis in Patients Undergoing Haematopoietic Stem Cell Transplantation: a Multicentre Italian Survey.

Authors:  Chiara Visintini; Margherita Venturini; Stefano Botti; Gianpaolo Gargiulo; Alvisa Palese
Journal:  Mediterr J Hematol Infect Dis       Date:  2019-09-01       Impact factor: 2.576

8.  Adjuvant treatment with adipose-derived mesenchymal stem cells (ADSC) reduces severe refractory hemorrhagic cystitis after RIC-PBSCT: A case report.

Authors:  Ruixue Yang; Gang Chen; Maria Muhashi; Gulibadanmu Aizezi; Ming Jiang; Hailong Yuan
Journal:  Medicine (Baltimore)       Date:  2021-07-02       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.